TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Three-part Intervention to Improve Regular Care for Asthma After a Pediatric Emergency Department Visit: A Randomized Clinical Trial
Brief Summary: The study will assess the efficacy of a three-part Emergency Department (ED)-based "Asthma Belief and Control" intervention on healthcare utilization, asthma controller medication use, symptoms, and quality of life during the 6 months following an Emergency Department visit.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Asthma Communication Education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Asthma Education | Intervention Type: BEHAVIORAL; Name: Asthma Communication Education; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Standard Asthma Education; Assigned to Arm(s): 2
B: Arm Label: Control Subjects; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Subjects; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Subjects | Intervention Type: BEHAVIORAL; Name: Intervention Subjects; Assigned to Arm(s): Intervention Subjects
C: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Three-part Intervention to Improve Regular Care for Asthma After a Pediatric Emergency Department Visit: A Randomized Clinical Trial
Brief Summary: The study will assess the efficacy of a three-part Emergency Department (ED)-based "Asthma Belief and Control" intervention on healthcare utilization, asthma controller medication use, symptoms, and quality of life during the 6 months following an Emergency Department visit.


Options:
A: Arm Label: Control Subjects; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Subjects; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Subjects | Intervention Type: BEHAVIORAL; Name: Intervention Subjects; Assigned to Arm(s): Intervention Subjects
B: Arm Label: Group 2: community video group; Type: EXPERIMENTAL; Interventions: Behavioral: patient role played community video, Behavioral: Community video group | Arm Label: Group three: both videos group; Type: EXPERIMENTAL; Interventions: Behavioral: both videos group | Arm Label: Group four: pamphlet group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pamphlet group | Arm Label: Group one: knowledge video group; Type: EXPERIMENTAL; Interventions: Behavioral: physician-led knowledge video, Behavioral: knowledge video | Intervention Type: BEHAVIORAL; Name: patient role played community video; Assigned to Arm(s): Group 2: community video group | Intervention Type: BEHAVIORAL; Name: both videos group; Assigned to Arm(s): Group three: both videos group | Intervention Type: BEHAVIORAL; Name: Pamphlet group; Assigned to Arm(s): Group four: pamphlet group | Intervention Type: BEHAVIORAL; Name: physician-led knowledge video; Assigned to Arm(s): Group one: knowledge video group | Intervention Type: BEHAVIORAL; Name: Community video group; Assigned to Arm(s): Group 2: community video group | Intervention Type: BEHAVIORAL; Name: knowledge video; Assigned to Arm(s): Group one: knowledge video group
C: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone counseling intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telephone counseling intervention; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Hypertonic Resuscitation for Blunt Trauma
Brief Summary: The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.


Options:
A: Intervention Type: DRUG; Name: Hypertonic Saline-Dextran Solution; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Fluid resuscitation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution; Assigned to Arm(s): N/A
C: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloids | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Colloids | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Crystalloids; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Colloids; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer
Brief Summary: The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy).


Options:
A: Arm Label: Cetuximab Plus FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Arm Label: FOLFIRI Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab Plus FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); Assigned to Arm(s): Cetuximab Plus FOLFIRI, FOLFIRI Alone
B: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: erlotinib (Tarceva), Drug: bevacizumab (Avastin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab (Avastin) | Intervention Type: DRUG; Name: erlotinib (Tarceva); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bevacizumab (Avastin); Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer
Brief Summary: The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy).


Options:
A: Arm Label: TAS-102; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): N/A
C: Arm Label: Panitumumab plus best supportive care; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab | Arm Label: Best Supportive Care; Type: OTHER; Interventions: Other: Best supportive care | Intervention Type: OTHER; Name: Best supportive care; Assigned to Arm(s): Best Supportive Care | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab plus best supportive care
D: Arm Label: Regorafenib (Stivarga, BAY73-4506)+BSC; Type: EXPERIMENTAL; Interventions: Drug: Regorafenib (Stivarga, BAY73-4506), Other: Best Supportive Care (BSC) | Arm Label: Placebo+BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Regorafenib (Stivarga, BAY73-4506); Assigned to Arm(s): Regorafenib (Stivarga, BAY73-4506)+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo+BSC, Regorafenib (Stivarga, BAY73-4506)+BSC

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects With Metastatic Colorectal Cancer
Brief Summary: The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and subsequently determined to have progressive disease.


Options:
A: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A
B: Arm Label: Arm B: FOLFOXIRI & bevacizumab (inclusion completed); Type: EXPERIMENTAL; Interventions: Drug: FOLFOXIRI with bevacizumab | Arm Label: Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed); Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFOX/ FOLFIRI with bevacizumab | Arm Label: Arm D: FOLFOX/FOLFIRI & panitumumab; Type: EXPERIMENTAL; Interventions: Drug: FOLFOX/ FOLFIRI with panitumumab | Arm Label: Arm C: FOLFOX/ FOLFIRI & bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFOX/ FOLFIRI with bevacizumab | Intervention Type: DRUG; Name: FOLFOX/ FOLFIRI with bevacizumab; Assigned to Arm(s): Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed), Arm C: FOLFOX/ FOLFIRI & bevacizumab | Intervention Type: DRUG; Name: FOLFOXIRI with bevacizumab; Assigned to Arm(s): Arm B: FOLFOXIRI & bevacizumab (inclusion completed) | Intervention Type: DRUG; Name: FOLFOX/ FOLFIRI with panitumumab; Assigned to Arm(s): Arm D: FOLFOX/FOLFIRI & panitumumab
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
D: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects With Metastatic Colorectal Cancer
Brief Summary: The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and subsequently determined to have progressive disease.


Options:
A: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: FOLFIRI | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: FOLFIRI | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): 1, 2
B: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B
D: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)
Brief Summary: The specific aims are to determine the incidence of medication errors related to antimicrobial prophylaxis for cardiovascular surgery, joint replacement surgery, and hysterectomies across a heterogeneous sample of hospitals; identify organizational and practitioner factors associated with error rates, and evaluate the effectiveness of a multifaceted intervention in reducing prophylaxis error rates compared to written feedback alone in a sample of 44 hospitals enrolled in the study using a rigorous group-randomized design.


Options:
A: Intervention Type: BEHAVIORAL; Name: Quality improvement strategies; Assigned to Arm(s): N/A
B: Arm Label: minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: professional audit and feedback (guideline adherence) | Arm Label: maximal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: patient education, Behavioral: professional audit and feedback (guideline adherence), Behavioral: professional education (communication/shared decision making), Other: information tools | Intervention Type: BEHAVIORAL; Name: patient education; Assigned to Arm(s): maximal intervention | Intervention Type: BEHAVIORAL; Name: professional audit and feedback (guideline adherence); Assigned to Arm(s): maximal intervention, minimal intervention | Intervention Type: BEHAVIORAL; Name: professional education (communication/shared decision making); Assigned to Arm(s): maximal intervention | Intervention Type: OTHER; Name: information tools; Assigned to Arm(s): maximal intervention
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2
D: Arm Label: ATP III; Type: EXPERIMENTAL; Interventions: Behavioral: Palm-Pilot Intervention | Arm Label: JNC 7; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Palm-Pilot Intervention | Intervention Type: BEHAVIORAL; Name: Palm-Pilot Intervention; Assigned to Arm(s): ATP III, JNC 7

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)
Brief Summary: The specific aims are to determine the incidence of medication errors related to antimicrobial prophylaxis for cardiovascular surgery, joint replacement surgery, and hysterectomies across a heterogeneous sample of hospitals; identify organizational and practitioner factors associated with error rates, and evaluate the effectiveness of a multifaceted intervention in reducing prophylaxis error rates compared to written feedback alone in a sample of 44 hospitals enrolled in the study using a rigorous group-randomized design.


Options:
A: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
B: Intervention Type: BEHAVIORAL; Name: Quality improvement strategies; Assigned to Arm(s): N/A
C: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
D: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB)
Brief Summary: STOP-DUB is a multicenter randomized clinical trial that is assessing the efficacy and effectiveness of hysterectomy versus endometrial ablation (EA) for dysfunctional uterine bleeding (DUB) in women for whom medical management has not provided relief.


Options:
A: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: hysterectomy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: endometrial ablation; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
Brief Summary: The purpose of this study is to determine the levels of testosterone and/or estradiol at which changes in bone turnover, body composition, strength, sexual function etc. begin to occur in older men. This information may help determine when to intervene with hormone replacement therapy in aging men.


Options:
A: Arm Label: Group 1: 0 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 2: 1.25 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 3: 2.5 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 4: 5 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 5: 10* g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 6: Placebo/Placebo (PBO/PBO); Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): Group 1: 0 g/day, Group 2: 1.25 g/day, Group 3: 2.5 g/day, Group 4: 5 g/day, Group 5: 10* g/day, Group 6: Placebo/Placebo (PBO/PBO) | Intervention Type: DRUG; Name: Goserelin acetate; Assigned to Arm(s): Group 1: 0 g/day, Group 2: 1.25 g/day, Group 3: 2.5 g/day, Group 4: 5 g/day, Group 5: 10* g/day, Group 6: Placebo/Placebo (PBO/PBO)
B: Intervention Type: DRUG; Name: PPAR alpha; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: PPAR alpha; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: A